Michael Sassano Michael Sassano currently serves as the CEO and Chairman of the Board for Somai Pharmaceuticals, an Ireland-based company focused on the cultivation, extraction, and distribution of cannabinoid-containing pharmaceutical products throughout the European Union. Before this position, Michael built one of the largest and most technologically advanced cultivation companies in the U.S. State of Nevada, called Solaris Farms. Michael built Solaris from a private equity start-up to a major player in the competitive Las Vegas market. With Somai, Michael is now leveraging his experience building a thriving cannabis company in the West Coast market - which he considers to be the best in the world in terms of cannabis growing and product development - and his success in leading Solaris from the ground-up to one of the top private companies in Nevada. He will now be turning his full attention to the European Union and building scalable high out-put cultivation and extraction facilities in various strategic countries as Europe develops its market. As the continent comes online, Somai will be positioned as one of the top global pharmaceutical distributors of medical-grade cannabis. This user account status is Approved Why GMP is the Future of Quality Control for the Global Industry 3 years ago in: Compliance and Regulations, Standards and Certification no comments SPAC Mania: The Biggest Cannabis Boom Is Yet To Come 3 years ago in: Banking, Finance & Real Estate, Op-Ed no comments Navigating Regulatory Hurdles in Specific Countries 3 years ago in: Europe no comments 9 Things to Consider When Raising Capital for Startups in Europe 3 years ago in: Banking, Finance & Real Estate no comments The Good The Bad and The Ugly, What Europe Can Learn from the U.S. and Canadian Cannabis Industries 3 years ago in: Europe, Op-Ed no comments Will Europe’s Cannabis Industry Follow More of a Pharmaceutical Model than Earlier Markets? 4 years ago in: Europe, International no comments Challenges for US Companies Entering the EU 4 years ago in: Europe, News & Insights, Op-Ed no comments